The present invention describes novel methods for using Treprostinil or
its derivative, or a pharmaceutically acceptable salt thereof, for the
treatment and/or prevention of ischemic lesions, such as digital ulcers,
in subjects with scleroderma (including systemic sclerosis), Buerger's
disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions
that cause such lesions. The invention also relates to kits for treatment
and/or prevention of ischemic lesions, comprising an effective amount of
Treprostinil or its derivative, or a pharmaceutically acceptable salt
thereof.